Exact Imaging Commercializing Ultrasound Tech for Prostate Biopsies
Exact Imaging is a Toronto-based company dedicated to the development of high-resolution micro-ultrasound systems that can provide real-time imaging and biopsy guidance for the prostate. The company recently announced that they’ve raised a $21.5 million Series C round of funding.

Led by Lumira Capital and Vesalius Biocapital, the round includes the participation of several new investors such as Participatiemaatschappij Vlaanderen PMV based in Brussels, as well as a number of existing investors, including iGan Partners and Rowanwood Ventures.

The platform developed by Exact Imaging increases urologist’s ability to visualize specific areas of the prostate and target biopsies to those areas. It will also enhance their ability to perform systematic biopsy protocols.

According to the company’s website, they offer “the world’s first 29 Mhz micro-ultrasound system,” as well as the “world’s first multi-tier system with ultra high-resolution and conventional probes.”

The company was co-founded by Sam Ifergan and Randy Aucoin in 2013 with the goal of developing and commercializing “this novel high resolution technology in order to disrupt the market and enable new levels of clinical imaging.”

The system includes a number of advanced features, including “full instrument height adjustment, rotational keyboard, lightweight probe cables, and a variety of ergonomic features to suit a wide range of operator preferences and user settings.”

“As a founding investor in Exact Imaging and longtime supporter of the company, we have always believed in the potential of this high-resolution micro-ultrasound technology and the impact it could have on the urology marketplace,” said iGan managing partner Sam Ifergan.

The company plans to utilize this significant round of funding to commercialize its ExactVu micro-ultrasound system. While they plan on using a portion of PMV’s investment to open a new office in Flanders, Belgium, the company also has plans to expand both in the U.S. and in Europe.

“We are very pleased to have been able to achieve an investment of this magnitude from such a high-quality investment syndicate,” said Randy AuCoin, Exact Imaging’s president, CEO, and co-founder. “This financing will allow us to scale our commercial organization, aggressively implement our product roadmap, and help us realize the significant opportunity in the prostate biopsy and imaging marketplace.”

According to Dr. Gaston Matthyssens, Managing Partner of Vesalius Biocapital, “Exact Imaging’s micro-ultrasound technology has the potential to change the standard of patient care in the urological practice by providing the urologist with the very tool they have been seeking. Specifically, a solution for prostate biopsies that provides much better resolution, is controlled by the urologist, and is based on a known technology and workflow.”

“With resolution down to 70 microns or 0.07 of a millimeter,” he continues, “the ExactVu high resolution system provides a 300% improvement in imaging resolution compared to the traditional standard-of-care urological ultrasound system. Urologists now have a tool, designed around their workflow, to facilitate the detailed interrogation and visualization of suspicious regions and perform targeted prostate biopsies.”

###


Be sure to check out OnCorp Direct's service offering for Healthcare professionals
Share |
Posted by: DSR
Wednesday, February 1, 2017
Tag: Healthcare
Archive
Business Start Ups
Healthcare
Dental
Legal
Subscribe to the OnCorp Direct RSS feed and stay up to date with what's going on within the blog.
Address: 1033 Bay Street, Suite 313
Toronto, Ontario M5S 3A5 Canada
Email: info@oncorp.com
Phone: (416) 964-CORP (2677)
Toll Free: 1-800-461-7772
Fax: (416) 964-3975
Website: www.oncorp.com
Facebook: www.facebook.com/OnCorpDirect
Twitter: http://twitter.com/OnCorpDirect
RSS: http://blog.oncorp.com/oncorp-full.xml
To Comment on this blog, email: comments@serptastic.com
OnCorp Direct Blog est. 2010 | Site Maintained By: SERPtastic.com